Skip to main content
OpenTrials
Completed

NCT Number: NCT06503874

Improving Attention in Individuals With Long COVID-19

This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The goal of this project is to test the feasibility, acceptability and efficacy of an attention training intervention (Attention Process Training; APT-3) as a potential treatment for brain fog symptoms experienced by people with Long-Covid. There already is good empirical evidence to support the idea that the APT-3 treatment is feasible and effective in improving attention in people with acquired brain injuries, but information about its efficacy and acceptability in people with Long-Covid brain fog is lacking.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-65 years. Live in the Chicagoland area
  • A history of confirmed SARS-CoV-2 infection.
  • Subjective reports of cognitive symptoms that interfere with everyday activities, starting on or shortly after SARS-CoV-2 infection.
  • Continuation or development of Long-Covid brain fog 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation.
  • Objective attentional deficits as measured by the Conners CPT-312, and/or the Digit Span subtest (WAIS- III13).
  • Able to use a keyboard.
  • Able to understand and communicate in English.
  • Able to consent independently.

Exclusion criteria

  • Being hospitalized due to COVID-19 diagnosis for more than 3 days.
  • Pre-morbid neurological conditions that could potentially affect cognition, such as Parkinson's Disease, Alzheimer's Dementia, acquired brain injury.
  • Severe depression.
  • Currently enrolled in cognitive training or physical exercise training.
  • Receiving chemotherapy or radiation within last 6 months.
  • Active substance abuse.

Treatment and study plan

Attention Training

Other

The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).

Other names: APT-3

Music group

Other

This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.

Primary outcomes

  1. Number of participants who successfully completed at least 80% of the study tasks sessions

    Time frame: 2 years

    Recording the number of participants who completed at least 80% of the study sessions out of the number of all participants who enrolled in the study.

Secondary outcomes

  1. Change of scores in objective attention tests (i.e, CPT 3), pre- and post -intervention

    Time frame: 2 year

    The Conners Continuous Performance Test Third Edition™ (Conners CPT 3™)

Other outcomes

  1. Change of scores in objective attention tests (i.e, Digit Span), pre- and post -intervention

    Time frame: 2 year

    Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) - Digit Span Subtest

Sponsors and collaborators

Lead sponsor

Shirley Ryan AbilityLab

Other

Registry information

Official study title

Intensive Attention Training to Treat Brain Fog in Individuals With Long-Covid

Acronym: LongCovAtten

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 16, 2024
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.